SCHEMBL10085253

SCHEMBL10085253

C[C@H](NC(=O)c1cccc2nc(Nc3ccc(Cl)cc3)oc12)c1ccc(C=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HTR3A P46098 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
GPR139 Q6DWJ6 2/20 0.37
PTGER4 P35408 3/20 0.37
TACR3 P29371 1/20 0.37
GALK1 P51570 1/20 0.36
THRB P10828 1/20 0.36
PDE2A O00408 1/20 0.36
NTSR1 P30989 1/20 0.36
FFAR2 O15552 1/20 0.35
USP36 Q9P275 1/20 0.35
MAPT P10636 1/20 0.35
TRPV4 Q9HBA0 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10085248 0.88 PTGER4 (0.49) HDAC3HDAC1HDAC8HDAC6PTGER4
SCHEMBL12900455 0.86 HDAC3 (0.42) ALDH1A1HDAC3HDAC1HDAC8HDAC6
SCHEMBL12585200 0.77 PTGER4 (0.51) HDAC3HDAC1HDAC8HDAC6PTGER4
SCHEMBL12583785 0.75 HDAC3 (0.44) ALDH1A1HDAC3HDAC1HDAC8HDAC6
SCHEMBL12583769 0.75 RAB9A (0.49) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL12585207 0.75 PTGER4 (0.54) PTGER4
SCHEMBL988503 0.74 EGFR (0.46) MAPTSMN1; SMN2
SCHEMBL12583797 0.73 DRD2 (0.47) ALDH1A1HDAC1MEN1KMT2APTGER4
SCHEMBL12948806 0.71 GAA (0.51) ALDH1A1HDAC6MEN1KMT2AMAPT
SCHEMBL10085255 0.71 CAPN1 (0.46) ALDH1A1MEN1KMT2AGPR139THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2460787-A1 Amide compounds and their use as PGE2 antagonists. Astellas Pharma Inc. (JP) 2012-06-06 EP disclosed
US-20110028463-A1 AMIDE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028463-A1 AMIDE COMPOUNDS PTGER4, PTGER1, PTGER2 ALDH1A1 2220/4885HDAC3 306/4885HDAC1 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.